Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29543324 | 1.00 | ADRA2A (0.57) | ADRA2AADRA1ATAAR1NFKB1BLM | |
| SCHEMBL25075582 | 0.80 | ADRA2A (0.56) | ADRA2AADRA1ATAAR1NFKB1BLM | |
| SCHEMBL29543986 | 0.80 | TAAR1 (0.47) | ADRA2AADRA1ATAAR1GAAPOLB | |
| SCHEMBL20970906 | 0.80 | TAAR1 (0.47) | ADRA2AADRA1ATAAR1GAAPOLB | |
| SCHEMBL22910035 | 0.76 | ADRA2A (0.42) | ADRA2AADRA1ANFKB1BLMPMP22 | |
| Ethylamine SCHEMBL6314624 | 0.75 | TAAR1 (0.63) | TAAR1GAAPOLBGFER | |
| SCHEMBL7935113 | 0.75 | NFKB1 (0.71) | ADRA2AADRA1ATAAR1NFKB1BLM | |
| SCHEMBL14661745 | 0.75 | POLB (0.52) | TAAR1GAAPOLBGFER | |
| SCHEMBL8904463 | 0.74 | ADRA1A (0.56) | ADRA2AADRA1ANFKB1BLMPMP22 | |
| Thymoquinol Dimethylether SCHEMBL12613923 | 0.74 | POLB (0.66) | ADRA2AADRA1ATAAR1GAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043605-B2 | Deuterated empathogens | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12012380-B1 | Neuroplastogens and non-hallucinogenic serotonin 5-HT2A receptor modulators | KULEON LLC (US) | 2024-06-18 | — | — | US | disclosed |
| US-20240189296-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240190819-A1 | Neuroplastogens and Non-Hallucinogenic Serotonin 5-HT2A Receptor Modulators | KULEON LLC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240124411-A1 | Deuterated Empathogens | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. | 2024-04-18 | — | — | US | disclosed |
| US-20240122914-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2024-04-18 | — | — | US | disclosed |
| US-20240124397-A1 | METHODS OF TREATING PSYCHOLOGICAL DISORDERS THROUGH THE ADMINISTRATION OF SEROTONIN 5-HT2C RECEPTOR MODULATORS | Kuleon, LLC (US) | 2024-04-18 | — | — | US | disclosed |
| US-20240122913-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2024-04-18 | — | — | US | disclosed |
| WO-2024077203-A1 | SEROTONIN RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | KULEON LLC (US) | 2024-04-11 | — | — | WO | disclosed |
| EP-4333838-A1 | FUNGAL COMPOUND COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION | Turtle Bear Holdings, LLC (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20230210872-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2023-07-06 | — | — | US | disclosed |
| WO-2023122135-A1 | SEROTONIN RECEPTOR AGONISTS AND METHODS OF MAKING AND USING THE SAME | KULEON LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122320-A1 | POLYPODAL SEROTONERGIC COMPOUNDS AND PRODRUGS OF SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | KULEON LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| US-11660305-B2 | Tryptamine compositions for enhancing neurite outgrowth | TURTLE BEAR HOLDINGS, LLC (US) | 2023-05-30 | — | — | US | disclosed |
| US-11622971-B2 | — | — | 2023-04-11 | — | — | US | disclosed |
| WO-2023023298-A1 | HALLUCINOGENIC AND NON-HALLUCINOGENIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PSILOSTERICS, LLC (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20220160737-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2022-05-26 | — | — | US | disclosed |
| WO-2021101926-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | STAMETS PAUL EDWARD (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20210069170-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS, LLC | 2021-03-11 | — | — | US | disclosed |
| US-20190142851-A1 | COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID | CAAMTECH, INC. | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142851-A1 | COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID | CNR1, CNR2, HTR5A | ADRA2A 78/4885ADRA1A 223/4885TAAR1 84/4885 |
| US-11660305-B2 | Tryptamine compositions for enhancing neurite outgrowth | HTR1B, HTR6, BDNF | ADRA2A 288/4885ADRA1A 441/4885TAAR1 128/4885 |
| US-12043605-B2 | Deuterated empathogens | SLC18A2, SLC6A3, GAP43 | ADRA2A 183/4885ADRA1A 176/4885TAAR1 59/4885 |
| US-20220160737-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | ADRA2A 288/4885ADRA1A 441/4885TAAR1 128/4885 |
| US-20240190819-A1 | Neuroplastogens and Non-Hallucinogenic Serotonin 5-HT2A Receptor Modulators | HTR2A, HTR2C, HTR1A | ADRA2A 133/4885ADRA1A 399/4885TAAR1 43/4885 |
| US-20240122914-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | ADRA2A 288/4885ADRA1A 441/4885TAAR1 128/4885 |
| US-20240124397-A1 | METHODS OF TREATING PSYCHOLOGICAL DISORDERS THROUGH THE ADMINISTRATION OF SEROTONIN 5-HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR3B | ADRA2A 61/4885ADRA1A 202/4885TAAR1 31/4885 |
| US-20210069170-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | ADRA2A 288/4885ADRA1A 441/4885TAAR1 128/4885 |
| US-12012380-B1 | Neuroplastogens and non-hallucinogenic serotonin 5-HT2A receptor modulators | HTR2A, HTR2C, HTR1A | ADRA2A 133/4885ADRA1A 399/4885TAAR1 43/4885 |
| US-20230210872-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | ADRA2A 288/4885ADRA1A 441/4885TAAR1 128/4885 |
| US-20240124411-A1 | Deuterated Empathogens | SLC18A2, SLC6A3, GAP43 | ADRA2A 183/4885ADRA1A 176/4885TAAR1 59/4885 |
| US-20240122913-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | ADRA2A 288/4885ADRA1A 441/4885TAAR1 128/4885 |
| US-11622971-B2 | — | HTR6, HTR1B, BDNF | ADRA2A 138/4885ADRA1A 231/4885TAAR1 125/4885 |
| US-20240189296-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | ADRA2A 288/4885ADRA1A 441/4885TAAR1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.